Selecta Biosciences (SELB) Tops Q2 EPS by 14c

Selecta Biosciences (NASDAQ: SELB) reported Q2 EPS of $0.06, $0.14 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $39.27 million versus the consensus estimate of $13.78 million.

For earnings history and earnings-related data on Selecta Biosciences (SELB) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Boston Omaha Corporation (BOC) Misses Q2 EPS by 2c
• Assembly Biosciences (ASMB) Tops Q2 EPS by 53c